| 
Carolyn Shelton, Dr. Joseph Fix,
and Sam Campbell
|
Management
Sam Campbell, President and CEO
Dr. Joesph Fix, Director of Business
& Corporate Development
Matthew McClorey, CFO
Jahna Howell, Director of Laboratory Operations
Board of Directors
William P. Duncan is President of the Kansas
City Area Life Sciences Institute. Prior to joining the Life
Sciences Institute, Dr. Duncan was Vice President of Technical
Operations for Midwest Research Institute, providing oversight
for MRI's six technical divisions. From 1995 to 1999, Dr.
Duncan was responsible for MRI's Strategic Marketing Program
and the activities of MRI regional marketing representatives.
From 1988 to 1995, Dr. Duncan was President and Chief Operating
Officer of Oread Laboratories, Inc. He received a Ph.D. in
Organic Chemistry from Oklahoma State University in 1972.
He is a member of the American Association of Pharmaceutical
Scientists, American Chemical Society, International Association
of Radiopharmacology, International Society for the Study
of Xenobiotics and International Isotope Society (IIS), where
he served as a member of the Scientific Advisory Board and
on the editorial board of the Jounrnal of Labelled Compounds
and Radiopharmaceuticals. He is a member of the Board of Directors
of The University of Kansas Center for Research, Inc. (CRINC),
the Missouri Biotechnology Industry Organization, the Kansas
Biosciences Association, the Kansas City Area Life Sciences
Institute, and the Kansas City Economic Development Corporation.
He has received numerous awards, including the Ernst &
Young 1992 Entrepenuer of the Year Award and the MRI Council
of Principal Scientists Science Award in 1981 and the Enterprise
Award in 1997.
Sam D. Campbell is President and CEO of CritiTech,
Inc. and has over twenty years of experience in managing early
stage life science and technology companies. He currently
is also the President of Campbell-Becker, Inc., a company
that specializes in assisting early stage companies properly
organize and finance their growth. He and his associates have
provided start-up capital to numerous life science companies
and worked with them to develop their company strategy and
its implementation. Most recently, Mr. Campbell has been developing
the Lawrence Life Sciences Center. The focus of the Center
is to commingle life science companies, researchers, university
spin-off companies, and technical/IP support personnel in
an effort to foster the growth of the life science industry
in the Kansas City/Lawrence area. Part of the support effort
involves the construction of a sophisticated bio/chem wet
lab that houses early stage life science companies.
Matthew McClorey is President and CEO of
Lawrence Regional Technology Center (LRTC). Prior to joining
LRTC, Mr. McClorey was the Vice President of Business Development
and Portfolio Management for the Kansas Technology Enterprise
Corporation (KTEC), where he evaluated start-up companies
for seed capital investments. He also managed a portfolio
of high-technology debt and equity investments, drafted and
negotiated investment agreements and provided management consulting
services to portfolio companies. Mr. McClorey came to KTEC
from Deloitte Consulting, where he was employed as a senior
consultant in the communications practice. While at Deloitte,
he worked with Fortune 500 companies providing strategy and
information technology consulting services. Mr. McClorey earned
his J.D. and M.B.A. from the University of Kansas and his
B.A. in Business from Benedictine College.
Bala Subramaniam, Ph. D. is a co-founder
of CritiTech. He is currently the Dan F. Servey Distinguished
Professor of Chemical and Petroleum Engineering and the Director
of the National Science Foundation Engineering Research Center
for Environmentally Beneficial Catalysis at the University
of Kansas (KU). Dr. Subramaniam obtained a Bachelor's degree
in chemical engineering from the University of Madras, India
and a Ph. D. degree in chemical engineering from the University
of Notre Dame. He joined the KU chemical and petroleum engineering
department in 1985, and recently served as chair of his department.
He has held visiting Professorships at the Institute of Process
Engineering, ETH in Zurich (Switzerland), University of Nottingham
(UK) and at the University of California, Davis. Dr. Subramaniam's
primary research interests are in catalysis, reaction engineering
and crystallization, with emphasis on developing sustainable
processes.. In recent years, his research has focused on systematically
exploiting the tunable physical and transport properties of
CO2-based solvents in developing novel catalytic, particle
formation and particle coating processes. He has authored
100+ research publications including 12 patents, presented
invited seminars at 70+ universities and companies, and delivered
keynote/plenary lectures at 20+ international conferences.
Dr. Subramaniam has received several awards for his teaching
and research, including the Dow Outstanding Young Faculty
Award from the American Society for Engineering Education;
the Gould Award for Teaching and the Miller Award for Research
from the KU School of Engineering; the Silver Anniversary
Teaching Award from the University of Kansas, and a Higuchi
Research Achievement Award from KU, the highest recognition
for research given by the University of Kansas. 
Jim Baxendale has worked for over thirty
years in the Kansas City biomedical community. Currently,
he serves as the Director of Technology Transfer and Intellectual
Property for the University of Kansas. Jim’s responsibilities
include the commercialization of faculty research, securing
patents and copyrights, negotiating licenses, research agreements,
confidentiality agreements, material transfer agreements and
facilitating the formation of start-up companies. The
KU Technology Transfer Office also provides internship opportunities
for students and co-facilitates a Biomedical Product Design
course in the School of Engineering.
Jim holds a Bachelor of Science Degree in Medical Technology,
a Master of Science in Microbiology from the University of
Missouri-Kansas City, and an MBA from the Rockhurst University
Executive Fellows MBA Program. For the Association of Medical
Device Manufacturers, in Washington, D.C., Jim served as a
member of the Board of Directors, Secretary and President.
He was appointed by the Commissioner of the Food and Drug
Administration to the Medical Device Good Manufacturing Practices
Advisory Committee for a 4-year term. Jim served as Chairman
of the Silicon Prairie Technology Association Bioscience Network
Steering Committee for four years, and has functioned as a
Business Counselor, Instructor and Consultant for the Kauffman
Foundation Fast Trac program for the last 8 years.
Dr. Joseph A. Fix, Director of Business and Corporate
Development and a pharmaceutical industry consultant, has
over 25 years experience in the drug delivery and pharmaceutical
industry in addition to his experience in working in the micro
and nanoparticle pharmaceutical arena. Dr. Fix has held a
number of executive positions in the pharmaceutical industry.
Most recently he was President and COO of Cydex, Inc. Previously,
he was EVP and COO of NanoSystems, Inc., a unit of Elan Corporation.
Before joining Elan, he was President and CTO of Yamanouchi
Pharma Technologies and Associate Director of Biological Sciences
for ALZA Corporation. He began his career with Merck and Company,
advancing to Associate Director, Biopharmaceutics for the
INTERx research division. Dr. Fix holds a Ph.D. in neurophysiology
from the University of Kansas and an MBA from Pepperdine University.
He has held adjunct faculty positions at the University of
Southern California, Purdue University, and the University
of Kansas. He is the author of numerous publications and holds
17 patents in the drug delivery area.
|
